Precigen Inc (PGEN)

Precigen's stock has increased by 117.96% in the past six months. In August 2025, PAPZIMEOS received full FDA approval. In September 2025, Precigen announced up to $125 million in non-dilutive financing. In October 2025, the company announced long-term follow-up results highlighting ongoing durable complete responses after treatment with PAPZIMEOS. In November 2025, Precigen reported its Q3 2025 financial results, with revenue exceeding forecasts but EPS missing, leading to stock fluctuations. The EMA validated the Marketing Authorization Application for PAPZIMEOS in November 2025. In December 2025 and January 2026, the stock experienced fluctuations due to profit-taking and concerns over the patient base for PAPZIMEOS. In January 2026, Precigen showcased commercialization momentum and market adoption of PAPZIMEOS at the J.P. Morgan Healthcare Conference.

Information directly detailing the demand seasonality for Precigen, Inc.'s products and services is limited. Demand for its products is likely driven by disease prevalence, clinical trial outcomes, regulatory approvals, and physician adoption rather than traditional seasonal consumer patterns. The recent FDA approval and commercialization of PAPZIMEOS suggest a growing demand for rare disease treatments. Product launches and clinical milestones are key drivers of interest and potential demand. The patient hub enrollment for PAPZIMEOS doubling since November 2025 also indicates growing adoption and demand for this specific product.

Precigen, Inc. is a U.S.-based biopharmaceutical company focused on gene and cell therapies using precision technology, operating in the biotechnology and healthcare industries with a focus on immuno-oncology, autoimmune disorders, and infectious diseases. The company utilizes the AdenoVerse platform for gene delivery, the UltraCAR-T platform for CAR T cell therapies, and the ActoBiotics platform for delivering therapeutic payloads at disease sites. Precigen also provides UltraPorator, an electroporation device, and develops research models and services. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020.

Precigen, Inc. is headquartered in Germantown, Maryland, United States. The commercialization of PAPZIMEOS is underway in the US, with nationwide prescribing and expanding private health plan coverage. The EMA has validated the Marketing Authorization Application for PAPZIMEOS, indicating potential expansion into international markets.

Precigen's brand reputation has been positively influenced by the FDA approval of PAPZIMEOS and positive long-term follow-up results. The rapid commercialization momentum further strengthens its reputation. However, the Q3 2025 EPS miss and the company's history of financial losses could be points of concern. Analysts generally maintain a "Buy" consensus rating.

Precigen, Inc. has a mixed ownership structure, with institutional, insider, and retail investors. Randal J. Kirk is the largest individual shareholder, owning 74.48% of the company. Helen Sabzevari, the CEO, holds 0.94% of the company. Third Security, LLC, holds 30.04% of the shares. Precigen has 277 institutional owners and shareholders holding a total of 133,169,261 shares. Major institutional owners include Patient Capital Management, LLC, Tang Capital Management Llc, BlackRock, Inc., Vanguard Group Inc, State Street Corp, Geode Capital Management, Llc, Iridian Asset Management Llc/ct, LMORX - Patient Opportunity Trust Class R and IWM - iShares Russell 2000 ETF. Institutional investors are primarily drawn to Precigen for its growth prospects in the biotechnology sector.